StreetInsider.com News Articles

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in San Francisco, CA. The H.C. Wainwright 28th Annual Global Investment Conference will take place at the Lotte New York Palace Hotel in New York City. Management will provide a brief corporate overview and be available for

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

The Emeryville, Calif.-based antibody discovery technology licensor now expects to end 2026 with cash and cash equivalents in the range of $49 million to $53 million, up from its prior guidance of $37 million to $41 million.

Chief Executive Officer Matt Foehr attributed the revision to business development and licensing activity. "Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook," he said.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity.

“Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executive Officer of OmniAb. “Our business at OmniAb continues to strengthen as the reach of our novel technologies expands and as our partnerships become deeper

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb and Eli Lilly reach ion channel drug discovery deal

Mon, 17 Aug 2026 06:01:20 -0400

OmniAb, Inc. (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program, according to a press release from the Emeryville, California-based company.

Under the terms of the agreement, OmniAb will receive an upfront payment and is eligible to receive up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The therapeutic target and modality were not disclosed.

The collaboration will use OmniAb's technology platform and its ion channel discovery and screening capabilities.

"We are pleased to enter into this important new relationship with

OmniAb and Eli Lilly reach ion channel drug discovery deal

Mon, 17 Aug 2026 06:01:20 -0400

The collaboration will use OmniAb's technology platform and its ion channel discovery and screening capabilities.

"We are pleased to enter into this important new relationship with

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening.

“We are pleased to enter into this important new relationship with Lilly,” said Matt Foehr, OmniAb’s Chief Executive Officer. “Lilly is focused on delivering medicines to address major unmet medical needs and our differentiated expertise and established technologies that relate to ion channels

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

Form SCHEDULE 13G/A OmniAb, Inc. Filed by: Whitefort Capital Management, LP

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932200.html

Form SCHEDULE 13G/A OmniAb, Inc. Filed by: Whitefort Capital Management, LP

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932200.html

OmniAb (OABI) Tops Q2 EPS by 7c; Offers Guidance

Thu, 06 Aug 2026 16:29:38 -0400

OmniAb (NASDAQ: OABI) reported Q2 EPS of ($0.05), $0.07 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $13.41 million versus the consensus estimate of $4.95 million.

GUIDANCE:

OmniAb sees FY2026 revenue of $32-36 million, versus the consensus of $30.8 million.

For earnings history and earnings-related data on OmniAb (OABI) click here.

OmniAb (OABI) Tops Q2 EPS by 7c; Offers Guidance

Thu, 06 Aug 2026 16:29:38 -0400

OmniAb (NASDAQ: OABI) reported Q2 EPS of ($0.05), $0.07 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $13.41 million versus the consensus estimate of $4.95 million.

GUIDANCE:

OmniAb sees FY2026 revenue of $32-36 million, versus the consensus of $30.8 million.

For earnings history and earnings-related data on OmniAb (OABI) click here.

Form 10-Q OmniAb, Inc. For: Jun 30

Thu, 06 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260806/26884654.html

Form 10-Q OmniAb, Inc. For: Jun 30

Thu, 06 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260806/26884654.html

Form 8-K OmniAb, Inc. For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884044.html

Form 8-K OmniAb, Inc. For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884044.html